A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease

被引:92
作者
Ayati, Bruce P. [1 ]
Edwards, Claire M. [2 ]
Webb, Glenn F. [3 ]
Wikswo, John P. [4 ,5 ,6 ,7 ]
机构
[1] Univ Iowa, Dept Math, Iowa City, IA 52242 USA
[2] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Vanderbilt Ctr Bone Biol, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Dept Math, Nashville, TN 37235 USA
[4] Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA
[5] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37235 USA
[6] Vanderbilt Univ, Dept Phys & Astron, Nashville, TN 37235 USA
[7] Vanderbilt Univ, Vanderbilt Inst Integrat Biosyst Res & Educ, Stevenson Ctr 6809, Nashville, TN 37235 USA
基金
美国国家卫生研究院; 美国国家科学基金会;
关键词
HUMAN MULTIPLE-MYELOMA; PROTEASOME INHIBITOR; IN-VIVO; OSTEOBLAST; BORTEZOMIB; RESORPTION; GROWTH; OSTEOCLASTS; PREDICTS; INDEXES;
D O I
10.1186/1745-6150-5-28
中图分类号
Q [生物科学];
学科分类号
090105 [作物生产系统与生态工程];
摘要
Background: Multiple myeloma is a hematologic malignancy associated with the development of a destructive osteolytic bone disease. Results: Mathematical models are developed for normal bone remodeling and for the dysregulated bone remodeling that occurs in myeloma bone disease. The models examine the critical signaling between osteoclasts (bone resorption) and osteoblasts (bone formation). The interactions of osteoclasts and osteoblasts are modeled as a system of differential equations for these cell populations, which exhibit stable oscillations in the normal case and unstable oscillations in the myeloma case. In the case of untreated myeloma, osteoclasts increase and osteoblasts decrease, with net bone loss as the tumor grows. The therapeutic effects of targeting both myeloma cells and cells of the bone marrow microenvironment on these dynamics are examined. Conclusions: The current model accurately reflects myeloma bone disease and illustrates how treatment approaches may be investigated using such computational approaches.
引用
收藏
页数:15
相关论文
共 38 条
[1]
Abildgaard N, 1998, EUR J HAEMATOL, V61, P128
[2]
Complex Dynamics of Osteoclast Formation and Death in Long-Term Cultures [J].
Akchurin, Timur ;
Aissiou, Tayeb ;
Kemeny, Naomi ;
Prosk, Erin ;
Nigam, Nilima ;
Komarova, Svetlana V. .
PLOS ONE, 2008, 3 (05)
[3]
RECRUITMENT OF NEW OSTEOBLASTS AND OSTEOCLASTS IS THE EARLIEST CRITICAL EVENT IN THE PATHOGENESIS OF HUMAN MULTIPLE-MYELOMA [J].
BATAILLE, R ;
CHAPPARD, D ;
MARCELLI, C ;
DESSAUW, P ;
BALDET, P ;
SANY, J ;
ALEXANDRE, C .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (01) :62-66
[4]
BATAILLE R, 1990, CANCER-AM CANCER SOC, V66, P167, DOI 10.1002/1097-0142(19900701)66:1<167::AID-CNCR2820660130>3.0.CO
[5]
2-9
[6]
Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia [J].
Bozec, Aline ;
Bakiri, Latifa ;
Hoebertz, Astrid ;
Eferl, Robert ;
Schilling, Arndt F. ;
Komnenovic, Vukoslav ;
Scheuch, Harald ;
Priemel, Matthias ;
Stewart, Colin L. ;
Amling, Michael ;
Wagner, Erwin F. .
NATURE, 2008, 454 (7201) :221-U61
[7]
Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo [J].
Edwards, Claire M. ;
Lwin, Seint T. ;
Fowler, Jessica A. ;
Oyajobi, Babatunde O. ;
Zhuang, Junling ;
Bates, Andreia L. ;
Mundy, Gregory R. .
AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (05) :268-272
[8]
DOES MYELOMA SECRETE AN OSTEOBLAST INHIBITING FACTOR [J].
EVANS, CE ;
GALASKO, CSB ;
WARD, C .
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 1989, 71 (02) :288-290
[9]
Bone marrow stromal cells regulate caspase 3 activity in leukemic cells during chemotherapy [J].
Fortney, JE ;
Zhao, W ;
Wenger, SL ;
Gibson, LF .
LEUKEMIA RESEARCH, 2001, 25 (10) :901-907
[10]
A bone remodelling model coupling microdamage growth and repair by 3D BMU-activity [J].
García-Aznar, JM ;
Rueberg, T ;
Doblare, M .
BIOMECHANICS AND MODELING IN MECHANOBIOLOGY, 2005, 4 (2-3) :147-167